In the pipeline: Brentuximab vedotin (SGN-35)
Today's featured lymphoma treatment in the pipeline is the antibody drug conjugate brentuximab vedotin.
Name: Brentuximab vedotin
Class: Antibody drug conjugate (ADC)
Type: Targeted treatment
FDA to date: In Phase II/III trials. FDA approval expected in late 2011.
Manufacturer: Seattle Genetics
Indications: Hodgkin lymphoma, anaplastic large T-cell (non-Hodgkin) lymphoma
A few words: Brentuximab vedotin is arguably generating more hype and excitement than any other lymphoma treatment in the pipeline right now. it is riding the high of outstanding press following very positive data against both Hodgkin's and ALCL reported at the 2010 American Society of Hematology meeting in December. Most expect Seattle Genetics to receive FDA approval for the treatment sometime in 2011.
Brentuximab vedotin brings together an anti-CD30 monoclonal antibody and the synthetic antimicrotubule agent monomethyl auristatin E (MMAE). Once in the body, the monoclonal antibody acts as a targeting system, seeking out cancer cells and delivering its cytotoxic payload (MMAE) into the malignant cell. Efficacy appears very high with a relatively low toxicity profile.
Click here to see clinical trials involving brentuximab vedotin.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
